tbuckley/cabot-search huggingface dataset:
Abstract P6-10-19: Bone mineral density(BMD) monitoring in postmenopausal women with early stage estrogen and/or progesterone receptor positive breast cancer on aromastase inhibitor(AI) therapy at University of Toledo medical center. A quality improvement project
Authors: Asma Taj, Sadik Khuder, Iman Mohamed
Journal: Cancer Research (2015)

Abstract Background More than 70% of breast cancer patients develop endocrine-responsive disease with estrogen receptor (ER)-positive or progesterone receptor-positive tumors or both [1] and require endocrine treatment with either estrogen blockage or ablation. The aromatase inhibitors are highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer. However, their use is associated with accelerated bone loss and an increase in fracture risk(2, 3) Method Post menopausal patients with early stage breast cancer( stage I and stage II) which was ER and/or PR positive and who were on AI therapy were included. Total patients 243.Stage I (101) and stage II (142).Agents used were Anastrazole, letrozole, exemestane .BMD (bone mineral density monitoring)was done by DEXA(Dual-energy X-ray absorptiometry) scan, and compared with national guidelines. Results 243 patients were included. At 0 years(at start of AI therapy) 150(62%) did not get a DEXA scan,40(16.4%) had normal DEXA scan, 48(19.8% )had osteopenia and 5( 2%) had osteoporosis. At 2 years from AI therapy 126(51.8%) did not get a DEXA scan, 35(14.4%) had normal DEXA scan, 73(30%) had osteopenia and 9(3.7%) had osteoporosis. At 5 years from AI therapy 180(74%) did not get a DEXA scan,21(8.6%) had normal DEXA scan, 35(14.4%) had osteopenia and 7(2.8%) had osteoporosis. Anastrazole and letrozole were equally associated with osteopenia/osteoporosis. Only 50% of patients with osteoporosis(10/21) received treatment for osteoporosis. Conclusions Although there is evidence of negative impact of the aromatase inhibitors on bone, our data still show a poor application of the recommendations in order to prevent osteoporosis related to the administration of these drugs. Part of the problem is the mixed literature on diagnosis and management of osteoporosis. Also medicare covers for a DEXA scan only once very two years. The national compliance for managing AI induced bone loss is very low which points out tthat this is a global problem. Our suggestion is a more active implementation of the guidelines, also by means of a greater collaboration between the oncologist and the specialist in osteoporosis, and the offer of a diagnostic and therapeutic pathway. Citation Format: Asma Taj, Sadik Khuder, Iman Mohamed. Bone mineral density(BMD) monitoring in postmenopausal women with early stage estrogen and/or progesterone receptor positive breast cancer on aromastase inhibitor(AI) therapy at University of Toledo medical center. A quality improvement project [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-10-19.
Abstract P6-05-02: Expression of ING1b-derived peptide inhibits viability of breast cancer cells and promotes apoptosis
Authors: Oleksandr Boyko, Karl Riabowol
Journal: Cancer Research (2015)

Abstract The ING1b protein is a type II tumor suppressor and a stoichiometric member of HDAC-containing protein complexes. Primarily by altering chromatin structure, ING1b contributes to regulation of gene expression, senescence and apoptosis. Mislocalization and decreased levels of ING1b are commonly observed in human tumors and cancer cell lines. Multiple independent studies in varied cell types report that ING1b overexpression promotes apoptosis. Since the inactivation of apoptosis pathways is frequent in cancer cells, modulating ING1b expression in tumors may serve as a viable approach for cancer therapy. We have defined the minimal ING1b region that confers apoptotic function as estimated by the levels of PARP cleavage, FACS analysis and using an Annexin V binding assay. We have established that ING1b-derived peptides containing its third alpha helix (A3H) and NLS/NTS domains are able to induce apoptosis at levels comparable to those of full length ING1b. The A3H-NLS/NTS peptide exhibited strong nucleolar localization characteristic of full length ING1b. Cells overexpressing the full length ING1b and A3H-NLS/NTS peptide showed similar changes in cell morphology characteristic of apoptosis and exhibited increased levels of PARP cleavage. While the A3H region that includes the N-terminal part of the highly conserved Lamin Interacting Domain (LID) was necessary but not sufficient, the NLS/NTS domain that mediates nuclear and nucleolar localization of ING1b was required and partially sufficient for induction of apoptosis. Adenoviral-mediated expression of A3H-NLS/NTS peptide in cells of osteosarcoma, glioblastoma and breast cancer origins resulted in strong reduction of cell viability. Depending on the cell line, treating cells with 45 MOI of virus expressing A3H-NLS/NTS peptide resulted in a 60 - 85% decrease in cancer cell survival compared to cells treated with the control construct (Ad-GFP), and the highly transformed triple negative tumorigenic MDA-MB-468 breast cancer line was sensitive to the peptide when infected with 5 MOI of A3H-NLS/NTS adenovirus. These pro-apoptotic effects were found to be dose and time dependent. Furthermore, using p53 wild-type, p53 mutant and p53-null cancer cell lines we demonstrated that the effects of A3H-NLS/NTS expression on cell survival and apoptosis were independent of p53-status. The evaluation of the synergy between the A3H-NLS/NTS peptide and common chemotherapeutic agents is currently ongoing. Our long-term goal is to develop ING1b-based therapeutics that can be used as an adjuvant therapy in combination with the existing breast cancer treatments. Citation Format: Oleksandr Boyko, Karl Riabowol. Expression of ING1b-derived peptide inhibits viability of breast cancer cells and promotes apoptosis [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-05-02.
Abstract 4711: The Prevalence and Determinant Factors of Intracoronary Thrombus Formation After Various Types of Drug-Eluting Stents Implantation: Optical Coherence Tomography Study
Authors: Jung-Sun Kim, Sang Min Park, Myeong-Ki Hong, Chunyu Fan, Young-Guk Ko, Donghoon Choi, Yangsoo Jang
Journal: Circulation (2009)
Prognostic Value of Mid-Regional Pro-Adrenomedullin Levels Taken on Admission and Discharge in Non–ST-Elevation Myocardial Infarction
Authors: Onkar S. Dhillon, Sohail Q. Khan, Hafid K. Narayan, Kelvin H. Ng, Joachim Struck, Paulene A. Quinn, Nils G. Morgenthaler, Iain B. Squire, Joan E. Davies, Andreas Bergmann, Leong L. Ng
Journal: Journal of the American College of Cardiology (2010)
Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements
Authors: Helen L Thomson, Arsene-Joseph Basmadjian, Andrew J Rainbird, Mehdi Razavi, Jean-Francois Avierinos, Patricia A Pellikka, Kent R Bailey, Jerome F Breen, Maurice Enriquez-Sarano
Journal: Journal of the American College of Cardiology (2001)
Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias
Authors: Thorsten Braun, marie Magdelaine Coude, Jeannig Berrou, Sibyl Bertrand, Eugenia Riveiro, Patrice Herait, Andre Baruchel, Hervé Dombret, Claude Gardin
Journal: Blood (2013)
THE VALUE OF A MIXTURE OF POWDERED MILK AND ALKALI FOR NEUTRALIZING THE GASTRIC ACIDITY OF PATIENTS WITH PEPTIC ULCER
Authors: Paul H. Wosika, Edward S. Emery
Journal: Annals of Internal Medicine (1936)

Article1 February 1936THE VALUE OF A MIXTURE OF POWDERED MILK AND ALKALI FOR NEUTRALIZING THE GASTRIC ACIDITY OF PATIENTS WITH PEPTIC ULCERPAUL H. WOSIKA, M.D., EDWARD S. EMERY JR., M.D.PAUL H. WOSIKA, M.D.Search for more papers by this author, EDWARD S. EMERY JR., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-9-8-1078 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince Sippy introduced his method of treating patients affected with peptic ulcer, there has been no unanimity of opinion among the medical profession concerning its therapeutic value. Those who oppose the treatment do so largely on the ground that large amounts of alkali are contraindicated, and that the results do not justify the time and trouble which the treatment entails. Its enthusiastic advocates maintain that complete neutralization of the gastric contents can be obtained if the treatment is carried out properly and that better results will follow this therapy. They argue that the poor results claimed for the therapy by...Reference1. WOSIKAEMERY PHES: The effectiveness of the Sippy regimen in neutralizing the gastric juice of patients if the amount of alkali is not varied. (See p. 1070 in this issue of the ANNALS.) Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*Received for publication October 18, 1935.From the Medical Clinic of the Peter Bent Brigham Hospital. The expenses of this study were defrayed by the Upjohn Company. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGASTRIC ANTACID AND ANTI-SECRETORY DRUGS: A SURVEY BASED PRIMARILY ON THEIR EFFECTS UPON GASTRIC SECRETION IN MAN*JOSEPH B. KIRSNER, M.D., Ph.D., F.A.C.P., WALTER L. PALMER, M.D., Ph.D., F.A.C.P., ERWIN LEVIN, M.A., M.D., ARTHUR P. KLOTZ, M.D.The control of gastric acidity in peptic ulcer by alkalinized powdered whole milk tablets 1 February 1936Volume 9, Issue 8Page: 1078-1090KeywordsHospitalsMilkPeptic ulcers ePublished: 1 December 2008 Issue Published: 1 February 1936 PDF downloadLoading ...
Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C‐Reactive Protein Level Is Below the Limit of Detection or If High‐Sensitivity C‐Reactive Protein Is Used: An Analysis in the DESIR Cohort
Authors: Pedro Machado, Victoria Navarro‐Compán, Robert Landewé, Floris A. van Gaalen, Christian Roux, Désirée van der Heijde
Journal: Arthritis & Rheumatology (2014)

Objective The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite measure of disease activity in axial spondyloarthritis. The aims of this study were to determine the most appropriate method for calculating the ASDAS using the C‐reactive protein (CRP) level when the conventional CRP level was below the limit of detection, to determine how low CRP values obtained by high‐sensitivity CRP (hsCRP) measurement influence ASDAS‐CRP results, and to test agreement between different ASDAS formulae. Methods Patients with axial spondyloarthritis who had a conventional CRP level below the limit of detection (5 mg/liter) were selected (n = 257). The ASDAS–conventional CRP with 11 different imputations for the conventional CRP value (range 0–5 mg/liter, at 0.5‐mg/liter intervals) was calculated. The ASDAS‐hsCRP and ASDAS using the erythrocyte sedimentation rate (ESR) were also calculated. Agreement between the ASDAS formulae was tested. Results The ASDAS‐hsCRP showed better agreement with the ASDAS‐CRP calculated using the conventional CRP imputation values of 1.5 and 2.0 mg/liter and with the ASDAS‐ESR than with other imputed formulae. Disagreement occurred mainly in lower disease activity states (inactive/moderate disease activity). When the CRP value was &lt;2 mg/liter, the resulting ASDAS‐CRP scores may have been inappropriately low. Conclusion When the conventional CRP level is below the limit of detection or when the hsCRP level is &lt;2 mg/liter, the constant value of 2 mg/liter should be used to calculate the ASDAS‐CRP score. There is good agreement between the ASDAS‐hsCRP and ASDAS‐ESR; however, formulae are not interchangeable.
Lower Serum Testosterone Associated with Elevated Polychlorinated Biphenyl Concentrations in Native American Men
Authors: Alexey Goncharov, Robert Rej, Serban Negoita, Maria Schymura, Azara Santiago-Rivera, Gayle Morse, David O. Carpenter
Journal: Environmental Health Perspectives (2009)

BackgroundPolychlorinated biphenyls (PCBs) and chlorinated pesticides are endocrine disruptors, altering both thyroid and estrogen hormonal systems. Less is known of action on androgenic systems.ObjectiveWe studied the relationship between serum concentrations of testosterone in relation to levels of PCBs and three chlorinated pesticides in an adult Native American (Mohawk) population.MethodsWe collected fasting serum samples from 703 adult Mohawks (257 men and 436 women) and analyzed samples for 101 PCB congeners, hexachlorobenzene (HCB), dichlorodiphenyldichloroethylene (DDE), and mirex, as well as testosterone, cholesterol, and triglycerides. The associations between testosterone and tertiles of serum organochlorine levels (both wet weight and lipid adjusted) were assessed using a logistic regression model while controlling for age, body mass index (BMI), and other analytes, with the lowest tertile being considered the referent. Males and females were considered separately.ResultsTestosterone concentrations in males were inversely correlated with total PCB concentration, whether using wet-weight or lipid-adjusted values. The odds ratio (OR) of having a testosterone concentration above the median was 0.17 [95% confidence interval (CI), 0.05–0.69] for total wet-weight PCBs (highest vs. lowest tertile) after adjustment for age, BMI, total serum lipids, and three pesticides. The OR for lipid-adjusted total PCB concentration was 0.23 (95% CI, 0.06–0.78) after adjustment for other analytes. Testosterone levels were significantly and inversely related to concentrations of PCBs 74, 99, 153, and 206, but not PCBs 52, 105, 118, 138, 170, 180, 201, or 203. Testosterone concentrations in females are much lower than in males, and not significantly related to serum PCBs. HCB, DDE, and mirex were not associated with testosterone concentration in either men or women.ConclusionsElevation in serum PCB levels is associated with a lower concentration of serum testosterone in Native American men.
Inhibition of NF-κB activity by Temozolomide involves O6-methylguanine induced reduction of p65 DNA-binding.
Authors: Bakhtiar Yamini, Xiaohong Yu, M Dolan, Michael Wu, Ralph Weichselbaum
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

3214 

It is well documented that the cytotoxicity of SN1 type alkylating agents like temozolomide (TMZ) occurs through the processing of O 6-methylguanine ( O 6-MeG) adducts by the mismatch repair (MMR) system. However, the damage signaling pathways downstream of MMR are not as well described. In this study, we examined the affect of TMZ on the pro-survival transcription factor, nuclear factor-κB (NF-κB). Using an NF-κB-responsive luciferase reporter assay, doses as low as 10 µM TMZ were found to inhibit endogenous and TNFα-induced NF-κB activity (IC50 of 75 µM) without affecting a control luciferase reporter. Inhibition by TMZ of endogenous and TNFα-induced RNA expression was confirmed in-vivo with quantitative reverse transcriptase-PCR of several NF-κB-dependent genes. Inhibition of NF-κB is independent of inhibitor of-κB alpha (IκBα) phosphorylation and degradation and, consistent with this, TMZ does not block TNFα-induced p65 nuclear translocation as analyzed by fluorescence imaging. The mechanism of NF-κB inhibition involves reduction of κB-element binding as assessed by EMSA, a finding confirmed in-vivo at the κB-site of the Bcl-XL and COX2 promoters. Time course studies demonstrate that inhibition of NF-κB begins after 6 hrs TMZ pretreatment and is maximal after 16 hrs. Using cells with varying O 6-alkylguanine-DNA alkyltransferase (AGT) activities (formed by stable AGT transfection and pharmacological AGT inhibition) and with varying MMR gene deletions, the presence of both O 6-MeG adducts and of a functioning MMR system are seen to be necessary for inhibition of NF-κB. Consistent with this, the SN1 methylating agent, methylnitrosurea (MNU), also inhibits NF-κB activity whereas the chloroethylating agent, BCNU, does not. Apoptosis and cytotoxicity were then assessed using annexin V binding and clonogenic assay. There is a significant reduction in cell killing when TNFα is administered at the same time as TMZ compared to TMZ alone (TMZ does not inhibit TNFα-induced NF-κB when administered at the same time as TNFα). When TNFα is given 16 hrs after TMZ, killing is significantly increased but only in cells where TMZ can inhibit NF-κB (i.e. cells with low AGT activity). Finally, in cells over-expressing p65, TMZ can neither inhibit NF-κB activity nor enhance the induction of apoptosis. In conclusion, this work illustrates a mechanism whereby TMZ inhibits NF-κB activity, a cellular process closely linked to the cytotoxicity of SN1 type alkylating agents. The reduction of NF-κB-dependent gene expression, following alkylator-induced injury, demonstrates a pathway by which MMR processing of DNA-damage can signal cell death.
Predicting patterns of sexual acts among homosexual and bisexual youths
Authors: M J Rotheram-Borus, M Rosario, H Reid, C Koopman
Journal: American Journal of Psychiatry (1995)

This longitudinal study examined predictors of patterns of change in HIV sexual risk acts among homosexual and bisexual adolescent males.A consecutive series of 136 homosexual and bisexual males aged 14-19 years were recruited into the study. Subjects were predominantly Hispanic (51%) and African American (31%) and seeking services at a homosexual-identified community-based agency in New York City. All subjects participated in an intensive HIV intervention program. Patterns of change in HIV sexual risk acts were based on assessments at four points (intake and 3, 6, and 12 months later) and were used to classify youths as demonstrating one of five patterns of anal and oral sexual acts: protected (anal: 45%, oral: 25%), improved (32% and 28%, respectively), relapse (5% and 8%), variable (8% and 15%), and unprotected (10% and 24%). Components of the health belief, self-efficacy, peer influence, coping, and distress models were assessed as predictors of these patterns.Protected and improved patterns of sexual risk acts were associated with low levels of anxiety, depression, and substance use and high self-esteem.These data suggest that HIV interventions must address non-HIV-related issues confronting youths in difficult life circumstances, particularly emotional distress and the role of peer networks for homosexual and bisexual youths.
Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia
Authors: S Terraneo, M Ferrer, I Martín-Loeches, M Esperatti, M Di Pasquale, V Giunta, M Rinaudo, F de Rosa, G Li Bassi, S Centanni, A Torres
Journal: Clinical Microbiology and Infection (2015)
IgG subclasses in the lungs of patients with interstitial pneumonitis following bone marrow transplantation
Authors: HJ Milburn, HG Prentice, JE Grundy
Journal: European Respiratory Journal (1993)

Subclasses of immunoglobulin G (IgG) were measured in bronchoalveolar lavage (BAL) fluid and serum from five normal volunteers and 25 bone marrow transplant (BMT) recipients, who developed 32 episodes of pneumonitis. Evidence for local production of the four subclasses was sought, to assess whether any observed deficiency was associated with any particular group of pulmonary infections. In the normal volunteers, IgG1 and IgG4 could be detected in BAL fluid from all subjects, with evidence for local production of IgG1 in one, and IgG4 in all five. IgG2 could be detected in BAL fluid from one subject, but IgG3 was undetectable in all normal BAL fluid. The BMT recipients differed from the normal volunteers mainly in the presence of IgG2 and IgG3 in BAL fluid. Furthermore, IgG4 could not be detected in BAL from seven. Furthermore, IgG4 could not be detected in BAL from seven episodes of pneumonitis (six patients). Bacteria, protozoa or fungi alone were isolated from five of these seven lavages, whereas pneumonitis associated with these organisms alone only occurred in 9 of the remaining 25 episodes of pneumonitis (19 patients) where there was also evidence for local production of IgG4. Moreover, 4 out of 7 patients with no detectable IgG4 in lavage developed secondary infections, whilst only 5 out of 19 patients producing IgG4 locally developed secondary infections (p = 0.05). Although there was individual variation within each group, levels of local production of both IgG1 and IgG4 tended, however, to be higher in patients who died from pneumonitis than in those who recovered, suggesting that this may be a poor prognostic marker.(ABSTRACT TRUNCATED AT 250 WORDS)
Abstract 10045: A Novel Approach to Define Type 4a Myocardial Infarction in Acute Coronary Syndrome Patients Undergoing Early Invasive Management: Insights From the CHAMPION PLATFORM Trial
Authors: Sergio Leonardi, Megan L Koehler, Adriano Truffa, Pierluigi Tricoci, Harvey White, C. Michael Gibson, Gregg W Stone, Robert A Harrington, Deepak L Bhatt, Kenneth W Mahaffey
Journal: Circulation (2011)

Background: Early PCI in pts with nSTE-ACS challenges the diagnosis of PCI-related MI. In CHAMPION PLATFORM, PCI was performed a median of 7.9 hours after admission, which may have hindered sensiti...
Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin’s-lymphoma: First interim results of a prospective randomised phase II study
Authors: M. Witzens-Harig, M. Hensel, J. Schmier, K. Neben, A. Benner, A. Krämer, A. D. Ho
Journal: Journal of Clinical Oncology (2005)

6722 Background: Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. Methods: To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. Results: So far 44 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (21 pts), follicular lymphoma (10 pts), mantle cell lymphoma (6 pts), primary mediastinal lymphoma (5 pts), marginal zone lymphoma (1 pt) and unclassified B-cell lymphoma (1 pt). No severe adverse events were observed during rituximab maintenance therapy. To date, all patients in the rituximab maintenance treatment arm are in continuous clinical remission. Importantly, in the observation arm 3 patients have relapsed. Conclusions: We conclude that rituximab maintenance therapy is feasable, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma and might protect against tumor relapse. Patient recruitment for this study is ongoing. No significant financial relationships to disclose.